United States: Understanding Medical Foods Under FDA Regulations

Last Updated: April 2 2014
Article by Claudia Lewis and Michelle C. Jackson

11.1 HISTORY OF MEDICAL FOODS

It took the Food and Drug Administration (FDA) 50 years after the passage of the Federal Food, Drug, and Cosmetic Act (FDCA) to formally define "medical foods." Prior to 1972, what we now would consider medical foods were regulated as prescription drugs under section 201(g)(1)(B) of the FDCA because of their role in mitigating serious adverse effects of diseases.1 Furthermore, prior to 1972, to market new products, manufacturers of medical foods were subject to onerous requirements, such as conducting complete drug trials, Investigational New Drug license applications, and New Drug Applications. Extremely time-consuming and cost-restrictive, such requirements choked the life out of medical food product innovation.

In 1972, the FDA reassessed its position on medical foods. This action was prompted by the agency's interest in fostering innovation in the development of medical foods and ensuring that such products were available to the public at a reasonable cost. However, due to safety concerns, the agency still sought to differentiate medical foods from general use foods. For example, the FDA reasoned that Lofenalac, an infant product designed for use in the dietary management of a rare genetic condition known as phenylketonuria (PKU), would be hazardous for healthy infants since it would be nutritionally inadequate for them. Therefore, the agency reclassified medical foods provided enterally (i.e., ingested via the digestive tract) as "foods for special dietary use," but injectable medical foods remained classified as drugs subject to the FDA's Drug Efficacy Study (DESI) program.2 In short, enterally administered nutrition was transferred to the food category while parenteral nutrition (i.e., injected into the body) retained its drug status.

Just one year later, when the agency made nutrition labeling mandatory for certain foods, it exempted certain types of foods for special dietary use from this requirement.3 In the preamble of the final rule, the FDA noted that nutrition labeling developed for foods intended for consumption by the general population was not well suited for some food products. Two foods for special dietary use were exempted from the nutrition labeling required for other food: (1) any food represented for use as the sole item of the diet and (2) foods represented for use solely under medical supervision in the dietary management of specific diseases and disorders.

A statutory definition of medical foods was finally promulgated in the Orphan Drug Amendments of 1988, Section 5b, Orphan Drug Act.4 A medical food was defined as "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."5 This statutory definition remains unchanged. Unfortunately, the legislative history of the amendments does not discuss the statutory definition of medical foods, thus failing to provide any additional information regarding the types of products Congress intended the definition to cover.6

Soon after the Orphan Drug Act Amendments, the FDA formally launched its initiative to improve the content and format of food labels with the publication of an Advanced Notice of Proposed Rulemaking (ANPR).7 As part of this overall initiative, the agency sought to resolve consumer confusion about food labels, aid consumers in health food decisions, and encourage product innovations so that manufacturers were given an incentive to improve the quality of the food and provide consumers with more healthy food choices.8 In the ANPR, the FDA asked the industry for guidance on a wide range of food-labeling issues to assist the agency in determining what, if any, changes to food labeling requirements were necessary, and it was quickly followed by four public hearings. With obvious public support for a thorough modernization of food labeling, the FDA published proposed regulations on July 19, 1990.9

It was during the comment period for the proposed regulations that Congress passed the Nutrition Labeling and Education Act of 1990 (NLEA), and on November 8, 1990, the legislation was signed into law by President George H. Bush. Not only did the NLEA affirm the FDA's authority to mandate nutrition labeling on most foods and clarify the agency's role in regulating nutrient content claims and health claims on food labels, it also incorporated the definition of medical foods contained in the Orphan Drug Amendments of 1988 into Section 403(q)(5)(A)(iv) of the FDCA and exempted medical foods from the nutrition labeling, health claim, and nutrient content claim requirements applicable to foods generally.10

Quickly thereafter, the FDA published a proposal to implement the mandatory nutrition labeling provisions of the NLEA, focusing specifically on the statutory exemption for medical foods.11 The proposal advised that the agency considered the statutory definition of medical foods to "narrowly constrain the types of products that can be considered to fall within this exemption,"12 a sentiment that the FDA has since reiterated time and again. Further, the FDA explained how medical foods are distinguished from the broader category of foods for special dietary use and from foods that make health claims. In the FDA's opinion, "under the supervision of a physician" within the NLEA meant "that the intended use of a medical food is for the dietary management of a patient receiving active and ongoing medical supervisions (e.g., in a health care facility or as an outpatient). The physician determines the food that is necessary to the patient's overall medical care,"13 and the patient visits the doctor for instructions on the use of the medical food. In its closing remarks on medical foods, the FDA stressed the vital public health interest in proper labeling of the nutrient content and purported uses of medical foods, which it noted may require a different manner and more detail than more traditional foods, adequate and appropriate directions for use, and product quality assurance. Thus, the agency declared that it intended to develop regulations covering these aspects "in the near future."14

In the Federal Register of January 6, 1993, the FDA published the final rule on mandatory nutrition labeling, which exempted medical foods from the nutrition labeling requirements and incorporated the statutory definition of medical foods into the agency's regulations at Section 101.9(j)(8).15 In the regulation, the FDA enumerated criteria intended to clarify the characteristics of medical foods. Accordingly, a food was defined as a medical food and, thus, not subject to the nutrition labeling requirements only if:

  1. It is a specially formulated and processed product (as opposed to a naturally occurring foodstuff used in its natural state) for the partial or exclusive feeding of a patient by means of oral intake or enteral feeding tube.
  2. It is intended for the dietary management of a patient who, because of therapeutic or chronic medical needs, has limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements, the dietary management of which cannot be achieved by the modification of the normal diet alone.
  3. It provides nutritional support specifically modified for the management of the unique nutrient needs that result from the specific disease or condition, as determined by medical evaluation.
  4. It is intended to be used under medical supervision.
  5. It is intended only for a patient receiving active and ongoing medical supervision wherein the patient requires medical care on a recurring basis for, among other things, instructions on the use of the medical food.16

This definition remains unchanged. In addition, the agency acknowledged that further clarification on the specific types of products the FDA considers medical foods would be helpful. Accordingly, it expressed its intention to address the issue in the future, but also noted its objective to develop much-needed medical food-labeling regulations.17

Citing the enactment of a statutory definition of medical food, the rapid increase in the variety and number of products marketed as medical foods, safety problems associated with the manufacture and quality control of these products, and the potential proliferation of fraudulent claims not supported by sound science, the FDA issued an ANPR on the "Regulation of Medical Foods" in 1996.18 The agency also sought to clarify the distinct differences between medical foods and foods for special dietary purpose. Though this ANPR was withdrawn in 2004, it largely remains the guiding force for industry understanding of the agency's views of medical food regulation.19

In the 1996 ANPR, the FDA acknowledged that the universe of products purporting to be medical foods had surpassed the statutory definition of a medical food to include foods that would more appropriately be categorized as foods for special dietary use. Looking to statutory language, the FDA sought to outline distinctions between these two types of foods, beginning with the meaning of "distinctive nutritional requirements" in the FDCA's definition of medical food. Pursuant to the statute, distinctive nutritional requirements must be based on recognized scientific principles and established by medical evaluation. Unfortunately, as the FDA noted in the ANPRM, the law does not define distinctive nutritional requirements. As a result, the agency proposed two possible interpretations of the phrase: (1) physiological interpretation and (2) alternative interpretation.

In the physiological interpretation, the FDA advised that distinctive nutritional requirements could be understood as referring to the body's need for specific amounts of nutrients to maintain homeostasis and sustain life. Under this interpretation, medical foods are

foods that are formulated to aid in the dietary management of a specific disease or health-related condition that causes distinctive nutritional requirements that are different from the nutritional requirements of healthy people. Foods for special dietary use, on the other hand, are foods that are specially formulated to meet a special dietary need, such as a food allergy or difficulty in swallowing, but that provide nutrients intended to meet ordinary nutritional requirements. The special dietary needs addressed by these foods do not reflect a nutritional problem per se; that is, the physiological requirements for nutrients necessary to maintain life or homeostasis addressed by foods for special dietary use are the same as those of normal, healthy persons. These foods are formulated in such a way that only the ingredients or physical form of the diet is different.20

On the other hand, the agency stated in the alternative interpretation that distinctive nutritional requirement may be construed to encompass physical and physiological limitations in a person's ability to ingest or digest conventional foods, as well as distinctive physiological nutrient requirements.21 Similarly, the Life Sciences Research Office of the Federation of American Societies for Experimental Biology (LSRO/FASEB Panel) noted in its 1990 Guidelines for the Scientific Review of Enteral Food Products for Special Medical Purposes that medical foods are for "patients with limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients contained therein, or (who) have other specialized medically determined nutrient requirements."22 After quoting this purpose, the FDA stated that the definition of distinctive nutritional requirement would include

foods intended for persons not able to ingest foods in certain physical forms (e.g., solid food), foods intended for persons who need a concentrated form of nutrition because of reduced appetite as a result of disease or convalescence, or foods intended for persons who may have other physical limitations on the amount or composition of food that they can consume. Although these types of conditions do not necessarily result in nutrient needs different from those of healthy persons, they represent a situation where it may be necessary that the food be formulated and manufactured within very narrow tolerances to ensure that the food provides most or all of the essential nutrients, as the person for whom the food is intended may not be able to eat a variety of foods to ensure that they meet their nutritional requirements.23

The second element that the FDA recognized as a distinguishing attribute of medical foods is the statutory requirement that a medical food be "formulated to be consumed or administered enterally under the supervision of a physician." As a general requirement, the patient must be receiving short- or long-term "active and ongoing" medical supervision (e.g., in a health care facility or as an outpatient).24 Unlike foods for special dietary purposes, the FDA views medical foods as an integral component of the patient's clinical management. Medical foods are not just simply recommended by a physician as a "part of an overall diet designed to reduce the risk of a disease or medical condition, to lose or maintain weight, or to ensure the consumption of a healthy diet."25

The final fundamental element of the definition of medical food addressed in the 1996 ANPR is the statutory requirement that a medical food be intended for the "specific dietary management" of a disease or condition. The FDA advised that the term "specific dietary management. . .evidences that Congress intended [medical] foods to be an integral part of the clinical treatment of patients."26 The agency also cited the LSRO/FASEB Panel's conclusion that the objective of incorporating the use of medical foods into patient management was, in part, to "ameliorate clinical manifestations of the disease," "favorably influence the disease process," and "positively influence morbidity and mortality (patient outcomes)."

Axona is an example of a medical food widely prescribed by physicians today. Axona, developed by Accera, is a medical food to provide the necessary nutrients for patients with Alzheimer's disease (AD). It has been clinically shown to improve cognitive function in some patients with AD, the leading cause of dementia, and does not increase metabolism. AD is a neurodegenerative disease characterized by a decline in the ability of the brain to metabolize glucose, even in its early stages. Axona is made from caprylic triglyceride and other medium chain triglycerides, which are converted to ketone bodies by the liver, an alternative energy source for cerebral neurons.

To read this article in full, please click here.

Originally published in the Nutraceutical and Functional Food Regulations in the United States and Around the World (Second Edition).

Footnotes

1 Advanced Notice of Proposed Rulemaking, Regulation of Medical Foods, 61 Fed. Reg. 60661, 60662 (Nov. 29, 1996).

2 The FDA recognized foods for "special dietary use" as early as 1941. Per regulation, the FDA stated that the term "special dietary uses" as applied to food for man, meant, among other things, "uses for supplying particular dietary needs which exist by reason of a physical, physiological, pathological or other condition, including but not limited to the conditions of disease, convalescence, pregnancy, lactation, allergic hypersensitivity to food, underweight, and overweight." Amendment to the General Regulations, Regulations for the Enforcement of the Federal Food, Drug, and Cosmetic Act, 6 Fed. Reg. 5921 (Nov. 22, 1941). This part of the regulation remains unchanged in the Code of Federal Regulations. See 21 C.F.R. y 105.3(a)(1) (September 17, 2013).

3 8 Fed. Reg. 2124, 2126 (January 19, 1973).

4 21 U.S.C. y 360ee(b)(3). Foods for special dietary use were often referred to as "orphan" because they were developed for the treatment of rare disorders that affect fewer than 200,000 persons in the United States. T.P. Labuza, Food Laws and Regulations: The Impact on Food Research, 36 Food Drug Cosmetic L.J. 293 (1981).

5 21 U.S.C. y 360ee(b)(3). The amendments also introduced a subcategory called "orphan medical foods" to be used in the management of ". . .any disease or condition that occurs so infrequently in the United States that there is no reasonable expectation that a medical food for such a disease or condition will be developed without assistance." Id.

6 61 Fed. Reg. 60662.

7 54 Fed. Reg. 32610 (August 8, 1989).

8 Virginia Wilkening, The Nutrition Labeling and Education Act of 1990 (November 27, 1991), http://www.nutrientdataconf.org/PastConf/NDBC17/8-2_Wilkening.pdf (last visited September 17, 2013).

9 55 Fed. Reg. 29456 (July 19, 1990).

10 Nutrition Labeling and Education Act y 2(a)(1990).

11 56 Fed. Reg. 60366 (November 27, 1991).

12 Id. at 60377.

13 Id.

14 Id., at 60378

15 58 Fed. Reg. 2079, 2151 (January 6, 1993).

16 21 C.F.R. y 101.9(j)(8).

17 58 Fed. Reg. 2151.

18 61 Fed. Reg. 60662.

19 69 Fed. Reg. 68834 (November 26, 2004). The FDA declared that: Because of competing priorities that have tied up FDA's limited resources, the agency has been unable to consider, in a timely manner, the issues raised by comments on the ANPRM, and does not foresee having sufficient resources in the near term to do so. Therefore, the agency is withdrawing this ANPRM. However, FDA believes that the basic principles described in the ANPRM provide an appropriate framework for understanding the regulatory paradigm governing medical foods. Therefore, FDA advises that it will continue to refer to the basic principles described in the ANPRM and in FDA's Medical Foods Compliance Program (CP 7321.002) when evaluating medical foods. With regard to the specific points made in the comment regarding regulation of medical foods, the comment is correct that the act exempts medical foods from the nutrition labeling, health claim and nutrient content claim requirements that are applicable to most other foods. However, all statements on food labels (including medical foods) must be truthful and not misleading (see section 403(a)(1) of the [A]ct). FDA advises that medical foods with false and misleading labeling are subject to enforcement action. The agency also advises that withdrawal of this ANPRM does not change the requirement that all ingredients used in medical foods must be approved food additive, GRAS, or otherwise exempt from the food additive definition. Medical foods that do not comply with this requirement are subject to enforcement action.

20 61 Fed. Reg. at 60667. The agency provided an example of a person possessing a special dietary need for a food that is in liquid form due to problems swallowing, noting that this special dietary need does not change his or her physiologic nutrient requirements. Along the same lines, a person allergic to gluten may need foods specially formulated, but the food would still provide the same amount of amino acids as needed by the general population because the quantitative and qualitative amount of overall protein required by the body is similar in both healthy and protein-sensitive individuals. Id.

21 Id.

22 J.M. Talbot, Guidelines for the Scientific Review of Enteral Food Products for Special Medical Purposes, Life Sciences Research Office, Federation of American Societies for Experimental Biology (1990).

23 61 Fed. Reg. at 60668.

24 Id. (citing 56 Fed. Reg. 60377).

25 Id., at 60668.

26 Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Wilson Elser Moskowitz Edelman & Dicker LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Wilson Elser Moskowitz Edelman & Dicker LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions